The Amin lab seeks to translate their understanding of metabolism into novel effective therapeutics for dieases associated with metabolic dysfunction.
My lab currently develops novel chemical tools for better understanding how modulation of nuclear receptors can influence metabolically related diseases. This includes neurodegenerative diseases (Alzheimer’s Disease), liver disease (NAFLD –NASH), and cardiometabolic diseases.
Our lab focuses upon novel target identification, rational drug library development based upon machine-based learning, and in silico development using Schroedinger and Gastroplus-based platforms.
- Alzheimer’s Disease
- Liver Disease
- Cross talk between Gut-liver and brain
- Drug Discovery
A major area of focus in the lab is related to developing novel therapeutics for fighting the progression of liver damage from nonalcoholic fatty liver disease (NAFLD) to Non-alcoholic steatotic hepatitis (NASH)
Current research utilizes transgenic animals and primary heart cells to better understand the mechanism by which activation of these nuclear receptors controls the promoter activity of specific gene targets which are involved in regulating myocardial energy homeostasis such as fatty acid metabolism and glucose modulation.